Prof Lancet speaks with ecancertv at ASH 2016 about CPX-351, a liposomal delivery of cytarabine and daunorubicin, for elderly patients with advanced AML.

Compared to the 7 3 schedule, he describes this subgroup as achieving better outcomes with acceptable toxicity profiles, and considers how CPX-351 might come to be used in other patient subgroups based on these results.

Video of the press conference in which these results were announced is available here, and more detail is available through ecancer news here.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.